JP2016539157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539157A5 JP2016539157A5 JP2016536607A JP2016536607A JP2016539157A5 JP 2016539157 A5 JP2016539157 A5 JP 2016539157A5 JP 2016536607 A JP2016536607 A JP 2016536607A JP 2016536607 A JP2016536607 A JP 2016536607A JP 2016539157 A5 JP2016539157 A5 JP 2016539157A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- benzimidazol
- methanone
- phenyl
- pyrrolidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- CXFXCNXDHHKIKS-VWLOTQADSA-N [(2S)-2-(6-bromo-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-ylphenyl)methanone Chemical compound Cc1ccc(-c2ncccn2)c(c1)C(=O)N1CCC[C@@]1(C)c1nc2cc(Br)cc(C)c2[nH]1 CXFXCNXDHHKIKS-VWLOTQADSA-N 0.000 claims 2
- NBGABHGMJVIVBW-QHCPKHFHSA-N [(2s)-2-(5-chloro-4-methyl-1h-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone Chemical compound N1([C@](CCC1)(C)C=1NC2=CC=C(Cl)C(C)=C2N=1)C(=O)C1=CC(OC)=CC=C1N1N=CC=N1 NBGABHGMJVIVBW-QHCPKHFHSA-N 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- XWYOWTGUVQJLBN-VWLOTQADSA-N [(2S)-2-(5,6-dimethoxy-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-(5-methyl-2-pyrazol-1-ylphenyl)methanone Chemical compound COc1cc2nc([nH]c2cc1OC)[C@]1(C)CCCN1C(=O)c1cc(C)ccc1-n1cccn1 XWYOWTGUVQJLBN-VWLOTQADSA-N 0.000 claims 1
- JAOXZMJRODOOQL-DEOSSOPVSA-N [(2S)-2-(5,6-dimethoxy-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone Chemical compound COC1=CC2=C(NC(=N2)[C@]2(N(CCC2)C(=O)C2=C(C=CC(=C2)OC)N2N=CC=N2)C)C=C1OC JAOXZMJRODOOQL-DEOSSOPVSA-N 0.000 claims 1
- VCQFUAGWDVFPQB-QFIPXVFZSA-N [(2S)-2-(5-bromo-6-fluoro-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound Cc1ccc(c(c1)C(=O)N1CCC[C@@]1(C)c1nc2cc(F)c(Br)cc2[nH]1)-n1nccn1 VCQFUAGWDVFPQB-QFIPXVFZSA-N 0.000 claims 1
- ZXEWKIMFKPFZMU-VWLOTQADSA-N [(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-(5-methyl-2-pyrimidin-2-ylphenyl)methanone Chemical compound Cc1ccc(-c2ncccn2)c(c1)C(=O)N1CCC[C@@]1(C)c1nc2c(C)c(Cl)ccc2[nH]1 ZXEWKIMFKPFZMU-VWLOTQADSA-N 0.000 claims 1
- XSONELHLKWDPKV-QHCPKHFHSA-N [(2S)-2-(6-bromo-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound Cc1ccc(c(c1)C(=O)N1CCC[C@@]1(C)c1nc2cc(Br)cc(C)c2[nH]1)-n1nccn1 XSONELHLKWDPKV-QHCPKHFHSA-N 0.000 claims 1
- JVWVAASSQXQBNF-QFIPXVFZSA-N [(2S)-2-[5-chloro-6-(trifluoromethyl)-1H-benzimidazol-2-yl]-2-methylpyrrolidin-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound ClC=1C(=CC2=C(NC(=N2)[C@]2(N(CCC2)C(=O)C2=C(C=CC(=C2)C)N2N=CC=N2)C)C1)C(F)(F)F JVWVAASSQXQBNF-QFIPXVFZSA-N 0.000 claims 1
- XSNFSFXKMQPCNT-DEOSSOPVSA-N [(2s)-2-(5,6-dimethoxy-1h-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@]1(C)C2=NC=3C=C(C(=CC=3N2)OC)OC)CCN1C(=O)C1=CC(C)=CC=C1N1N=CC=N1 XSNFSFXKMQPCNT-DEOSSOPVSA-N 0.000 claims 1
- DOWZCWSQZJMWOI-QFIPXVFZSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(2S)-2-methyl-2-[6-(trifluoromethoxy)-1H-benzimidazol-2-yl]pyrrolidin-1-yl]methanone Chemical compound Cc1ccc(c(c1)C(=O)N1CCC[C@@]1(C)c1nc2cc(OC(F)(F)F)ccc2[nH]1)-n1nccn1 DOWZCWSQZJMWOI-QFIPXVFZSA-N 0.000 claims 1
- VGDLIWVHXXDXQV-QFIPXVFZSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(2S)-2-methyl-2-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]pyrrolidin-1-yl]methanone Chemical compound CC=1C=CC(=C(C1)C(=O)N1[C@@](CCC1)(C1=NC2=C(N1)C=CC(=C2)C(F)(F)F)C)N2N=CC=N2 VGDLIWVHXXDXQV-QFIPXVFZSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2013060630 | 2013-12-04 | ||
| IBPCT/IB2013/060630 | 2013-12-04 | ||
| PCT/IB2014/066548 WO2015083094A1 (en) | 2013-12-04 | 2014-12-03 | Use of benzimidazole-proline derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539157A JP2016539157A (ja) | 2016-12-15 |
| JP2016539157A5 true JP2016539157A5 (OSRAM) | 2018-01-18 |
| JP6421185B2 JP6421185B2 (ja) | 2018-11-07 |
Family
ID=52347368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536607A Active JP6421185B2 (ja) | 2013-12-04 | 2014-12-03 | ベンゾイミダゾール−プロリン誘導体の使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9914721B2 (OSRAM) |
| EP (1) | EP3077391B1 (OSRAM) |
| JP (1) | JP6421185B2 (OSRAM) |
| KR (1) | KR102330133B1 (OSRAM) |
| CN (1) | CN105873921B (OSRAM) |
| AU (1) | AU2014358766B2 (OSRAM) |
| CA (1) | CA2930053A1 (OSRAM) |
| CL (1) | CL2016001349A1 (OSRAM) |
| CY (1) | CY1121089T1 (OSRAM) |
| DK (1) | DK3077391T3 (OSRAM) |
| EA (1) | EA029725B1 (OSRAM) |
| ES (1) | ES2696708T3 (OSRAM) |
| HK (1) | HK1225734B (OSRAM) |
| HR (1) | HRP20181710T1 (OSRAM) |
| HU (1) | HUE040555T2 (OSRAM) |
| IL (1) | IL245914B (OSRAM) |
| LT (1) | LT3077391T (OSRAM) |
| MA (1) | MA39165A1 (OSRAM) |
| MX (1) | MX366642B (OSRAM) |
| MY (1) | MY179605A (OSRAM) |
| PH (1) | PH12016500985B1 (OSRAM) |
| PL (1) | PL3077391T3 (OSRAM) |
| PT (1) | PT3077391T (OSRAM) |
| SA (1) | SA516371253B1 (OSRAM) |
| SI (1) | SI3077391T1 (OSRAM) |
| TR (1) | TR201815342T4 (OSRAM) |
| UA (1) | UA116053C2 (OSRAM) |
| WO (1) | WO2015083094A1 (OSRAM) |
| ZA (1) | ZA201604502B (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20170351T1 (hr) | 2012-06-04 | 2017-04-21 | Actelion Pharmaceuticals Ltd. | Derivati benzimidazol-prolina |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| NO3077389T3 (OSRAM) | 2013-12-03 | 2018-02-10 | ||
| HRP20181710T1 (hr) | 2013-12-04 | 2018-12-28 | Idorsia Pharmaceuticals Ltd | Uporaba derivata benzimidazol-prolina |
| US10196383B2 (en) | 2015-07-17 | 2019-02-05 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
| SG11201804223TA (en) | 2015-11-23 | 2018-06-28 | Sunshine Lake Pharma Co Ltd | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF |
| JP7182562B2 (ja) | 2017-05-03 | 2022-12-02 | イドーシア ファーマシューティカルズ リミテッド | ２－（［１，２，３］トリアゾール－２－イル）－安息香酸誘導体の製造 |
| JP2023521492A (ja) | 2020-04-19 | 2023-05-24 | イドーシア ファーマシューティカルズ リミテッド | ダリドレキサントの医学的用途 |
| EP4289834B1 (en) * | 2021-02-02 | 2025-11-26 | Medshine Discovery Inc. | Tetrahydropyrrolocyclic compound and application thereof |
| WO2023160004A1 (zh) * | 2022-02-25 | 2023-08-31 | 南京知和医药科技有限公司 | 具有镇痛活性的稠环化合物及其制备方法与用途 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3282927A (en) | 1964-05-21 | 1966-11-01 | Bristol Myers Co | 5-phenyl-4-thiazolylpenicillins |
| JP2001247569A (ja) | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
| AUPQ253199A0 (en) | 1999-08-30 | 1999-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Non-prostanoid prostaglandin I2-agonist |
| AU2001272476A1 (en) | 2000-06-16 | 2001-12-24 | Smithkline Beecham Plc | Piperidines for use as orexin receptor antagonists |
| WO2002028839A1 (en) | 2000-10-06 | 2002-04-11 | Neurogen Corporation | Benzimidazole and indole derivatives as crf receptor modulators |
| AU2002224885A1 (en) | 2000-11-28 | 2002-06-11 | Smithkline Beecham Plc | Morpholine derivatives as antagonists of orexin receptors |
| ES2299567T3 (es) | 2001-05-05 | 2008-06-01 | Smithkline Beecham Plc | N-aroilaminas ciclicas. |
| AU2002341123A1 (en) | 2001-05-05 | 2002-11-18 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| CZ20033437A3 (cs) | 2001-06-28 | 2004-09-15 | Smithkline Beecham P.L.C. | N-Aroylové cyklické aminové deriváty jako antagonisté orexinového receptoru |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
| GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
| GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| DE10240818A1 (de) | 2002-08-30 | 2004-05-13 | Grünenthal GmbH | Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate |
| DE60309481T2 (de) | 2002-09-18 | 2007-06-21 | Glaxo Group Ltd., Greenford | Cyclische n-aroylamine als orexinrezeptorantagonisten |
| GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| AR044586A1 (es) | 2003-06-04 | 2005-09-21 | Aventis Pharma Sa | Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| US7763638B2 (en) | 2004-03-01 | 2010-07-27 | Actelion Pharmaceuticals Ltd. | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| WO2005113522A1 (en) | 2004-05-07 | 2005-12-01 | Janssen Pharmaceutica, N.V. | Azole carboxamide inhibitors of bacterial type iii protein secretion systems |
| EP1604989A1 (en) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
| US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| GB0510142D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| HUP0500920A2 (en) | 2005-10-05 | 2007-07-30 | Richter Gedeon Nyrt | Oxadiazole derivatives, process for their preparation and their use |
| AU2007226203A1 (en) | 2006-03-15 | 2007-09-20 | Actelion Pharmaceuticals Ltd | Tetrahydroisoquinoline derivatives to enhance memory function |
| WO2008008517A2 (en) | 2006-07-14 | 2008-01-17 | Merck & Co., Inc. | Bridged diazepan orexin receptor antagonists |
| DE602007012910D1 (de) | 2006-08-15 | 2011-04-14 | Actelion Pharmaceuticals Ltd | Azetidinverbindungen als orexin-rezeptor-antagonisten |
| KR20090077051A (ko) | 2006-09-29 | 2009-07-14 | 액테리온 파마슈티칼 리미티드 | 3-아자-비시클로[3.1.0]헥산 유도체 |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| ATE496043T1 (de) | 2006-12-01 | 2011-02-15 | Actelion Pharmaceuticals Ltd | 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren |
| TW200833328A (en) | 2006-12-28 | 2008-08-16 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.1.0]hexane derivatives |
| WO2008087611A2 (en) | 2007-01-19 | 2008-07-24 | Actelion Pharmaceuticals Ltd | Pyrrolidine- and piperidine- bis-amide derivatives |
| CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| US20100222328A1 (en) | 2007-05-14 | 2010-09-02 | Hamed Aissaoui | 2-cyclopropyl-thiazole derivatives |
| US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008150364A1 (en) * | 2007-05-23 | 2008-12-11 | Merck & Co., Inc. | Cyclopropyl pyrrolidine orexin receptor antagonists |
| CN101796053A (zh) | 2007-07-03 | 2010-08-04 | 葛兰素集团有限公司 | 用作食欲素受体拮抗剂的哌啶衍生物 |
| AU2008272449A1 (en) | 2007-07-03 | 2009-01-08 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.3.0]octane compounds |
| GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
| EP2183246A2 (en) | 2007-07-27 | 2010-05-12 | Actelion Pharmaceuticals Ltd. | 2-aza-bicyclo-[3.3.0]-octane derivatives |
| AR067665A1 (es) | 2007-07-27 | 2009-10-21 | Actelion Pharmaceuticals Ltd | Derivados de trans-3- aza-biciclo ( 3.1.0) hexano |
| EP2185512B1 (en) | 2007-07-27 | 2010-12-29 | Actelion Pharmaceuticals Ltd. | Trans-3-aza-bicyclo[3.1.0]hexane derivatives |
| WO2009040730A2 (en) | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines and piperidines as orexin receptor antagonists |
| PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
| SI2225231T1 (sl) | 2007-12-18 | 2011-12-30 | Actelion Pharmaceuticals Ltd | Derivati aminotriazola kot alx agonisti |
| WO2009080533A1 (en) * | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Heteroaryl derivatives as orexin receptor antagonists |
| EP2247586B1 (en) | 2008-02-21 | 2012-04-25 | Actelion Pharmaceuticals Ltd. | 2-aza-bicyclo[2.2.1]heptane derivatives |
| GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
| CN102083827A (zh) | 2008-07-07 | 2011-06-01 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的噻唑烷化合物 |
| WO2010038200A1 (en) | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
| WO2010044054A1 (en) | 2008-10-14 | 2010-04-22 | Actelion Pharmaceuticals Ltd | Phenethylamide derivatives and their heterocyclic analogues |
| JP2012506375A (ja) | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト |
| WO2010060471A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| JP2012509912A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | 新規の化合物 |
| EP2358711A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| MX2011005800A (es) | 2008-12-02 | 2011-06-20 | Glaxo Group Ltd | Derivados de n{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4. 1.0]hept-4-il]metil}-2-heteroarilamina y sus usos. |
| AR074426A1 (es) | 2008-12-02 | 2011-01-19 | Glaxo Group Ltd | Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende |
| GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
| US20120035214A1 (en) | 2009-04-03 | 2012-02-09 | Merck Canada Inc. | Renin inhibitors |
| US20120040991A1 (en) | 2009-04-24 | 2012-02-16 | Glaxo Group Limited | 3-azabicyclo [4.1.0] heptanes used as orexin antagonists |
| JP5095035B2 (ja) | 2009-06-09 | 2012-12-12 | アクテリオン ファーマシューティカルズ リミテッド | フッ素化アミノトリアゾール誘導体 |
| EP2275421A1 (en) | 2009-07-15 | 2011-01-19 | Rottapharm S.p.A. | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction |
| KR101859409B1 (ko) | 2009-10-23 | 2018-05-18 | 얀센 파마슈티카 엔.브이. | 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로［3,4-ｃ］피롤 |
| US8680275B2 (en) | 2009-10-23 | 2014-03-25 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| US9062044B2 (en) | 2009-10-23 | 2015-06-23 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
| CA2788363A1 (en) | 2010-01-19 | 2011-07-28 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| CA2807000C (en) | 2010-08-24 | 2018-12-04 | Actelion Pharmaceuticals Ltd | Proline sulfonamide derivatives as orexin receptor antagonists |
| MX2013002927A (es) | 2010-09-24 | 2013-05-30 | Bristol Myers Squibb Co | Inhibidores del virus de la hepatitis c. |
| JP5847830B2 (ja) | 2010-11-10 | 2016-01-27 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | オレキシン受容体拮抗薬として有用なラクタム誘導体 |
| ES2541531T3 (es) | 2011-02-18 | 2015-07-21 | Actelion Pharmaceuticals Ltd. | Nuevos derivados de pirazol e imidazol útiles como antagonistas de orexina |
| EA024106B1 (ru) | 2011-11-08 | 2016-08-31 | Актелион Фармасьютиклз Лтд. | Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида |
| HRP20170351T1 (hr) * | 2012-06-04 | 2017-04-21 | Actelion Pharmaceuticals Ltd. | Derivati benzimidazol-prolina |
| EP2906553B1 (en) | 2012-10-10 | 2019-06-26 | Idorsia Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero)aryl)-pyrrolidin-1-yl]-methanone derivatives |
| WO2014141065A1 (en) | 2013-03-12 | 2014-09-18 | Actelion Pharmaceuticals Ltd | Azetidine amide derivatives as orexin receptor antagonists |
| NO3077389T3 (OSRAM) | 2013-12-03 | 2018-02-10 | ||
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| HRP20181710T1 (hr) | 2013-12-04 | 2018-12-28 | Idorsia Pharmaceuticals Ltd | Uporaba derivata benzimidazol-prolina |
-
2014
- 2014-12-03 HR HRP20181710TT patent/HRP20181710T1/hr unknown
- 2014-12-03 JP JP2016536607A patent/JP6421185B2/ja active Active
- 2014-12-03 HK HK16114187.6A patent/HK1225734B/en unknown
- 2014-12-03 DK DK14827273.5T patent/DK3077391T3/en active
- 2014-12-03 KR KR1020167017709A patent/KR102330133B1/ko active Active
- 2014-12-03 US US15/101,871 patent/US9914721B2/en active Active
- 2014-12-03 HU HUE14827273A patent/HUE040555T2/hu unknown
- 2014-12-03 MX MX2016007313A patent/MX366642B/es active IP Right Grant
- 2014-12-03 LT LTEP14827273.5T patent/LT3077391T/lt unknown
- 2014-12-03 CA CA2930053A patent/CA2930053A1/en not_active Abandoned
- 2014-12-03 EA EA201600434A patent/EA029725B1/ru not_active IP Right Cessation
- 2014-12-03 TR TR2018/15342T patent/TR201815342T4/tr unknown
- 2014-12-03 UA UAA201607117A patent/UA116053C2/uk unknown
- 2014-12-03 PT PT14827273T patent/PT3077391T/pt unknown
- 2014-12-03 WO PCT/IB2014/066548 patent/WO2015083094A1/en not_active Ceased
- 2014-12-03 PL PL14827273T patent/PL3077391T3/pl unknown
- 2014-12-03 MA MA39165A patent/MA39165A1/fr unknown
- 2014-12-03 EP EP14827273.5A patent/EP3077391B1/en active Active
- 2014-12-03 MY MYPI2016702036A patent/MY179605A/en unknown
- 2014-12-03 AU AU2014358766A patent/AU2014358766B2/en active Active
- 2014-12-03 CN CN201480065780.6A patent/CN105873921B/zh active Active
- 2014-12-03 ES ES14827273T patent/ES2696708T3/es active Active
- 2014-12-03 SI SI201430931T patent/SI3077391T1/sl unknown
-
2016
- 2016-05-26 PH PH12016500985A patent/PH12016500985B1/en unknown
- 2016-05-30 IL IL245914A patent/IL245914B/en active IP Right Grant
- 2016-06-01 SA SA516371253A patent/SA516371253B1/ar unknown
- 2016-06-02 CL CL2016001349A patent/CL2016001349A1/es unknown
- 2016-07-01 ZA ZA2016/04502A patent/ZA201604502B/en unknown
-
2018
- 2018-11-15 CY CY181101212T patent/CY1121089T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539157A5 (OSRAM) | ||
| JP2016034978A5 (OSRAM) | ||
| JP2016535795A5 (OSRAM) | ||
| JP2016106149A5 (OSRAM) | ||
| JP2016525102A5 (OSRAM) | ||
| JP2016508134A5 (OSRAM) | ||
| FI3406609T3 (fi) | Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina | |
| ME02150B (me) | Derivati piperidinona kao inhibitori mdm2 za lečenje kancera | |
| JP2015500225A5 (OSRAM) | ||
| JP2016523260A5 (OSRAM) | ||
| JP2017057230A5 (OSRAM) | ||
| EP4342540A3 (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| JP2013519675A5 (OSRAM) | ||
| JP2016510326A5 (OSRAM) | ||
| RU2015104537A (ru) | Способы лечения стромальных опухолей желудочно-кишечного тракта | |
| JP2016518337A5 (OSRAM) | ||
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| JP2014148535A5 (OSRAM) | ||
| JP2012193216A5 (OSRAM) | ||
| JP2015522018A5 (OSRAM) | ||
| JP2016522254A5 (OSRAM) | ||
| EA201891931A1 (ru) | Новые ингибиторы фосфатидилинозитол-3-киназы гамма | |
| JP2015516419A5 (OSRAM) | ||
| PH12015501945A1 (en) | Formulations of organic compounds | |
| EA201990664A1 (ru) | Производные 5-[2-(пиридин-2-иламино)-1,3-тиазол-5-ил]-2,3-дигидро-1h-изоиндол-1-она и их применение в качестве двойных ингибиторов фосфатидилинозитол-3-киназ дельта и гамма |